Patent ID: 8754216

Claim:
A method of treating an NK1 receptor mediated disease comprising: administering to a patient in need thereof an oral dosage form comprising an effective amount of at least one compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 are selected from the group consisting of alkyl, haloalkyl, alkyl substituted with one or more hydroxyl groups, —CN, alkynyl, —N(R 6 ) 2 , —N(R 6 )—S(O 2 )-alkyl, —N(R 6 )—C(O)—N(R 9 ) 2 , -alkylene-CN, -cycloalkylene-CN, -alkylene-O-alkyl, —C(O)-alkyl, —C(═N—OR 5 )-alkyl, —C(O)—O-alkyl, -alkylene-C(O)-alkyl, -alkylene-C(O)—O-alkyl, -alkylene-C(O)—N(R 9 ) 2 , with the proviso that at least one of R 1 and R 2 is —CN, W is ═C(R 8 )— or ═N—; X is —C(O)— or —S(O 2 )—; Y is selected from the group consisting of —CH 2 —, —O—, and —N(R 6 )—C(O)—, with the proviso that: (a) the nitrogen atom of —N(R 6 )—C(O)— is bonded to X, and (b) if R 1 and/or R 2 is and Y is —O—, X is not —S(O 2 )—; Z is —C(R 7 ) 2 , —N(R 6 )—, or —O—; R 3 is selected from the group consisting of H, and unsubstituted alkyl; R 4 is H; R 5 is H or alkyl; R 6 is selected from the group consisting of H, alkyl, cycloalkyl, and aryl; R 8 is selected from the group consisting of H, alkyl, cycloalkyl, and aryl; each R 7 is independently H or alkyl; or each R 7 , together with the ring carbon to which they are shown attached, form a cycloalkylene ring; R 8 is selected from the group consisting of H, alkyl, alkyl substituted with one or more hydroxyl groups, —N(R 6 ) 2 , —N(R 6 )—S(O 2 )-alkyl, —N(R 6 )—S(O 2 )-aryl, —N(R 6 )—C(O)-alkyl, —N(R 6 )—C(O)-aryl, alkylene-O-alkyl, and —CN; R 9 is selected from the group consisting of H, alkyl, and aryl, or each R 9 , together with the nitrogen to which they are shown attached, form a heterocycloalkyl ring; Ar 1 is unsubstituted phenyl; Ar 2 is phenyl substituted with 0-3 substituents selected from the group consisting of haloalkyl; n is 0, 1, or 2; and m is 1, 2 or 3.